MiNK Therapeutics to Provide Corporate Update and Second Quarter 2024 Financial Report
MiNK Therapeutics (NASDAQ: INKT), a clinical-stage biopharmaceutical company focused on developing allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies, has announced its plans to release second quarter 2024 financial results on August 13, 2024, before the market opens. The company will host a conference call and webcast at 8:30 a.m. ET on the same day to discuss the results and provide a corporate update. Interested parties can access the call via provided dial-in numbers or join the live webcast through the company's investor relations website.
MiNK Therapeutics (NASDAQ: INKT), un'azienda biopharmaceuticale in fase clinica focalizzata sullo sviluppo di terapie cellulari allogeniche pronte all'uso a base di cellule T naturali invarianti (iNKT), ha annunciato i suoi piani per rilasciare i risultati finanziari del secondo trimestre 2024 il 13 agosto 2024, prima dell'apertura del mercato. L'azienda organizzerà una conference call e una diretta streaming alle 8:30 a.m. ET dello stesso giorno per discutere i risultati e fornire un aggiornamento aziendale. Le parti interessate possono accedere alla chiamata tramite i numeri forniti o partecipare alla diretta streaming attraverso il sito web delle relazioni con gli investitori dell'azienda.
MiNK Therapeutics (NASDAQ: INKT), una compañía biofarmacéutica en etapa clínica especializada en el desarrollo de terapias celulares de tipo natural killer T invariantes (iNKT) alogénicas y listas para usar, ha anunciado sus planes para publicar los resultados financieros del segundo trimestre de 2024 el 13 de agosto de 2024, antes de la apertura del mercado. La compañía realizará una llamada de conferencia y una transmisión en vivo a las 8:30 a.m. ET en el mismo día para discutir los resultados y ofrecer una actualización corporativa. Las partes interesadas pueden acceder a la llamada a través de los números de marcación proporcionados o unirse a la transmisión en vivo a través del sitio web de relaciones con inversores de la compañía.
MiNK Therapeutics (NASDAQ: INKT)는 동종 이식을 위한 준비된 iNKT(불변 자연 살해 T 세포) 세포 치료제를 개발하는 데 중점을 둔 임상 단계의 생명공학 회사입니다. 이 회사는 2024년 2분기 재무 결과를 2024년 8월 13일에 시장 개장 전 발표할 계획을 발표했습니다. 같은 날 오전 8시 30분 ET에 결과를 논의하고 회사 업데이트를 제공하기 위해 컨퍼런스 콜 및 웹캐스트를 진행할 예정입니다. 관심 있는 분들은 제공된 전화를 통해 콜에 접속하거나 회사의 투자자 관계 웹사이트를 통해 실시간 웹캐스트에 참여할 수 있습니다.
MiNK Therapeutics (NASDAQ: INKT), une entreprise biopharmaceutique en phase clinique spécialisée dans le développement de thérapies cellulaires à base de cellules T naturelles invariantes (iNKT), a annoncé ses projets de publication des résultats financiers du deuxième trimestre 2024 le 13 août 2024, avant l'ouverture du marché. L'entreprise organisera une conférence téléphonique et un webinaire le même jour à 8h30 ET pour discuter des résultats et fournir une mise à jour de l'entreprise. Les parties intéressées peuvent accéder à l'appel via les numéros d'appel fournis ou rejoindre le webinaire en direct via le site Web des relations avec les investisseurs de l'entreprise.
MiNK Therapeutics (NASDAQ: INKT), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von allogenen, sofort einsatzbereiten, invariant natural killer T (iNKT) Zelltherapien spezialisiert hat, hat seine Pläne bekannt gegeben, die finanziellen Ergebnisse des zweiten Quartals 2024 am 13. August 2024, vor Markteröffnung, zu veröffentlichen. Das Unternehmen wird am selben Tag um 8:30 Uhr ET eine Telefonkonferenz und eine Webcast veranstalten, um die Ergebnisse zu besprechen und ein Unternehmensupdate zu geben. Interessierte Parteien können über die bereitgestellten Einwahlnummern an dem Anruf teilnehmen oder über die Website der Investor Relations des Unternehmens an dem Live-Webcast teilnehmen.
- None.
- None.
NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its second quarter 2024 financial results before the market opens on August 13, 2024. MiNK executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and to provide a corporate update.
Conference Call
Dial-in numbers: 646-307-1963 (New York), 800-715-9871 (USA & Canada)
Conference ID: 4021545
Webcast
A live webcast and replay of the conference call will be accessible from the Events & Presentations page of the Company’s website at https://investor.minktherapeutics.com/events-and-presentations and via https://edge.media-server.com/mmc/p/gwzqgg8t/.
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit https://minktherapeutics.com/ or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels.
Investor Contact
917-362-1370
Media Contact
781-674-4428
communications@minktherapeutics.com
FAQ
When will MiNK Therapeutics (INKT) release its Q2 2024 financial results?
What time is MiNK Therapeutics' (INKT) Q2 2024 earnings call scheduled for?
How can investors access MiNK Therapeutics' (INKT) Q2 2024 earnings call?
What is MiNK Therapeutics' (INKT) main focus in drug development?
